Avidity Partners Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Avidity Partners Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,063,000	Closed	-$2.29M	–	86
2024 Q3	$2.29M	Sell	1,063,000 -610,538	-36%	-$2.19M	0.12%	74
2024 Q2	$8.64M	Hold	1,673,538	–	–	0.37%	65
2024 Q1	$8.95M	Hold	1,673,538	–	–	0.29%	73
2023 Q4	$13M	Buy	1,673,538 +92,396	+6%	+$316K	0.48%	56
2023 Q3	$6.25M	Buy	1,581,142 +117,108	+8%	+$438K	0.25%	72
2023 Q2	$4.61M	Buy	1,464,034 +559,404	+62%	+$1.8M	0.16%	83
2023 Q1	$2.42M	Buy	904,630 +4,630	+0.5%	+$17.9K	0.08%	77
2022 Q4	$3.23M	Hold	900,000	–	–	0.07%	72
2022 Q3	$5.8M	Buy	+900,000	New	+$7.31M	0.12%	74

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Avidity Partners Management's SYRS Position: Q4 2024 in Review

Avidity Partners Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 1,063,000 shares — an estimated $2.29M sold.

Avidity Partners Management first reported a position in SYRS in Q3 2022 and held it in 9 quarters. The position peaked at $13M in Q4 2023. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

Avidity Partners Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Avidity Partners Management sold 1,063,000 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $2.29M.
Avidity Partners Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2022 and held it in 9 quarters.
Avidity Partners Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $13M in Q4 2023.
44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Avidity Partners Management's 13F filing for Q4 2024, filed 14 Feb 2025.